Investigation of Galactosylated Low Molecular Weight Chitosan-Coated Liposomes for Cancer Specific Drug Delivery
Purpose: To assess the hepatocyte targeting potential of galactosylated low molecular weight chitosan (Gal-LMWCs)-coated liposomes bearing doxorubicin hydrochloride (DOX).
Methods: Chitosan (CS) was depolymerized and lactobionic acid (LA) containing a galactose group was coupled with low molecular weight chitosan (LMWC) using carbodiimide chemistry. Two types of galactosylated polymers with variable degree of substitution were synthesized. Liposomes were prepared using film casting method, coated with the synthesized polymers and characterized for vesicle shape and size, polydispersity, zeta potential, drug entrapment, coating efficiency, in vitro drug release and cytotoxicity on human hepatoma cell line (HepG2).
Results: Coating efficiency was greater for the polymer with a lower degree of substitution. The liposomes formed were spherical in shape with a size range of 110 - 160 nm, drug entrapment of 92.14 - 96.37 % and zeta potential of 20.6 - 29.4 mV. Gal-LMWC(s)-coated liposomes exhibited a maximum of 65 % in vitro drug release in 24 h in a sustained fashion. The 50 % inhibitory concentration (IC50) values for liposomal formulations and drug solution were 2.81 and 5.98 μg/ml, respectively.
Conclusion: Gal-LMWC (s) coated liposomes containing DOX that demonstrate targetability to human hepatocellular carcinoma cell line (in vitro) have been successfully developed.
Keywords: Targeted delivery, Doxorubicin, Galactosylated, Chitosan, Hepatocellular, Carcinoma, Nanoparticles
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.